New Two-Drug attack on advanced lung cancer enters testing
NCT ID NCT07353957
Summary
This study is testing whether adding a new drug called petosemtamab to an existing immunotherapy (pembrolizumab) is safe and more effective for people newly diagnosed with advanced non-small cell lung cancer. It will involve about 180 adults whose cancer has spread and who have not yet received any treatment for it. The main goal is to see how many people's tumors shrink significantly from this combination.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER - NON SMALL CELL SQUAMOUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tennessee Site 1
RECRUITINGNashville, Tennessee, 37209, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tennessee Site 2
RECRUITINGChattanooga, Tennessee, 37403, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Site 1
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.